The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) last traded at $2.41, unchanged from the previous session.
ESPR stock price is now 20.42% away from the 50-day moving average and 8.70% away from the 200-day moving average. The market capitalization of the company currently stands at $474.85M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $2.50, BofA Securities recently Downgraded its rating from Neutral to Underperform for Esperion Therapeutics Inc (NASDAQ: ESPR). , while ‘JP Morgan’ rates the stock as ‘Neutral’
In other news, Warren Eric, Chief Commercial Officer sold 197 shares of the company’s stock on Nov 19 ’24. The stock was sold for $427 at an average price of $2.17. Upon completion of the transaction, the Chief Commercial Officer now directly owns 162,355 shares in the company, valued at $0.39 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 19 ’24, Officer Warren Eric bought 197 shares of the business’s stock. A total of $427 was incurred on buying the stock at an average price of $2.17. A total of 1.00% of the company’s stock is owned by insiders.
During the past 12 months, Esperion Therapeutics Inc has had a low of $1.15 and a high of $3.40. The fifty day moving average price for ESPR is $1.988 and a two-hundred day moving average price translates $2.21805 for the stock.
The latest earnings results from Esperion Therapeutics Inc (NASDAQ: ESPR) was released for 2024-09-30. The company reported revenue of $51.63 million for the quarter, compared to $33.97 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 52.0 percent.
